Presentation on: Pfizer and the Pharmaceutical Industry Fletcher Leung Analyst Investment Analysis Group February 15‚ 2002 Presentation Agenda • Industry Overview: Research Based Pharmaceuticals • Pfizer – Company Specifics – Performance – Growth Drivers • Valuation – Comparables Analysis – DCF • Recommendation February 15‚ 2002 Page 2 Investment Analysis Group 1 Industry Overview Economic •Cost Effective Demographic Sociocultural •Aging Population
Premium
Supply and Demand Pharmaceutical Industry In today ’s society‚ a large percentage of the population requires prescription drugs to treat injury or illness. In some cases‚ the need for drugs may be short term and in other cases‚ the drugs may be required for the remainder of an individual ’s life. In all cases‚ prescription drugs are not free; the individual or his or her insurance company pays. The type of drug and available substitutions generally drive the costs. In this paper‚ I will summarize
Premium Pharmacology Pharmaceutical industry Food and Drug Administration
EXECUTIVE SUMMARY Global Pharma Industry is likely to grow at a CAGR of 5% to US $ 1 Trillion by 2013 The Pharmaceuticals Industry in India is the world’s 3 largest in terms of volume and stands 14th in terms of sale. Domestic pharma sector benefitted from increased thrust on Rural Health through bigger budgetary allocations in the Budget of 2009-10 According to PWC in 2010‚ India joined the league of Top 10 global pharmaceutical markets in terms of sales by 2020 with value reaching
Premium Pharmaceutical industry Generic drug
ETHICAL ISSUES IN THE PHARMACEUTICAL INDUSTRY Ethical Issues in the Pharmaceutical Industry Abstract No one can deny that the pharmaceutical industry has made significant contributions to human progress. The pharmaceutical industry has been responsible for drugs that have saved millions of lives‚ cured many forms of cancer‚ and ensured that an AIDS diagnosis is no longer an automatic death sentence. Yet despite this there are questions that the public has on whether the industry has been fulfilling
Premium Physician Clinical trial Pharmaceutical industry
Table of Contents Introduction: 1 Bangladeshi Pharmaceutical Industry: 2 Industry Analysis: 2 Competitive Force 1: Rivalry among Existing Firms 3 Competitive Force 2: Threat of New Entrants 3 Competitive Force 3: Threat of Substitute Products 3 Competitive Force 4: Bargaining Power of Buyers 4 Competitive Force 5: Bargaining Power of Suppliers 4 Competitive Strategy Analysis: 5 Cost Leadership: 5 Product Differentiation: 5 Corporate Strategy Analysis: 6 Conclusion:………………………………………………………………………………………………………7
Premium Generic drug Pharmacology Pharmaceutical industry
Alliance Concrete Case Questions Each team should prepare a written report (2 to 3 pages) on this case. Please ensure you answer the following questions in your report. Note that question 1 requires you to do a financial projection of Alliance Concrete’s 2006 financial statements (using Excel). One team will be selected at random to lead the class discussion on the case and present their 2006 financial projections. 1. What is your best estimate of the 2006 financial statements? As a starting
Premium Finance Debt Bond
Global Pharmaceutical Industry Analysis September 21 2009 Dibakar Mitra (P08017) I Manoj Joshi (B08026) Table of Contents EXECUTIVE SUMMARY 3 INTRODUCTION 4 ORIGIN AND EVOLUTION 5 ENVIRONMENT ANALYSIS (PEST) 7 STRUCTURAL INDUSTRY ANALYSIS (PORTER) 8 STRATEGIC ISSUES FACING THE INDUSTRY 11 STRATEGIC GROUPS IN THE INDUSTRY ACCORDING TO MARKET/DRUG/FUNCTIONING 15 PROCESS FLOW: IMPORTANT FUNCTIONS 16 STRATEGIC RESPONSES TO CHALLENGES: SIMPLE CORRELATION BETWEEN GROUP
Premium Pharmaceutical industry
State intervention in the pharmaceutical industry: social advance or threat to innovation? By Ivan Topalovic Introduction 1/ The Product A/ European level‚ the “EMEA” B/ R.O.W. a) The Followers b) The non-Followers 2/ The Price A/ Worldwide parameters B/ Examples of price fixing per country 3/ The Place 4/ The Promotion Conclusion Appendix I Chronology in therapeutic innovation Appendix II Major pharmaceutical companies mergers / acquisitions
Premium Pharmacology Clinical trial Generic drug
YRH: Pharmaceutical Industry in China to 2020 Market Overview‚ Size‚ Share‚ Analysis‚ Technology Developments‚ Development Status‚ Trends‚ Structure‚ Production Value and Forecast Research Report Summary “Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies‚ Industry Trends‚ Environment‚ Regulation‚ Market Drivers‚ Restraints‚ Opportunities & Challengess” provides a detailed investigation of the market size‚ segmentation‚ key players‚ SWOT
Premium Pharmacology Pharmaceutical industry Food and Drug Administration
Melina Guzman Mrs. Reed Period: 4 November 7‚ 2011 The Truth about Pharmaceutical Industry “Greed is a bottomless pit which exhausts the person in an endless effort to satisfy the need without ever reaching satisfaction” (Erich). Living in today’s society it’s impossible for you not see advertisement for the Pharmaceutical industry. Whether it’s a billboard‚ a commercial or an elderly person wearing a sponsored rain jacket their advertisements are hard to miss. Every day we see these
Premium Pharmaceutical industry Pharmacology Clinical trial